Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
…, C Hu, Y Luo, L Chen, M Ye, J Huang, X Zhi… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring
Y Chang, B Tolani, X Nie, X Zhi, M Hu… - Therapeutics and clinical …, 2017 - Taylor & Francis
Circulating cell-free DNA (cfDNA) released by tumor cells, termed ctDNA, closely reflects
the heterogeneity of primary cancers and their metastases. As a noninvasive, real-time …
the heterogeneity of primary cancers and their metastases. As a noninvasive, real-time …
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies
…, PT Pham, MS Mulvihill, F Ziaei, H Zhang, B Su, X Zhi… - The Lancet, 2012 - thelancet.com
Background The frequent recurrence of early-stage non-small-cell lung cancer (NSCLC) is
generally attributable to metastatic disease undetected at complete resection. Management …
generally attributable to metastatic disease undetected at complete resection. Management …
[HTML][HTML] The Society for Translational Medicine: clinical practice guidelines for the postoperative management of chest tube for patients undergoing lobectomy
…, T Zhang, X Zhang, X Zhao, X Zhao, X Zhi… - Journal of thoracic …, 2017 - ncbi.nlm.nih.gov
The Society for Translational Medicine and The Chinese Society for Thoracic and Cardiovascular
Surgery conducted a systematic review of the literature in an attempt to improve our …
Surgery conducted a systematic review of the literature in an attempt to improve our …
Impact of examined lymph node count on precise staging and long-term survival of resected non–small-cell lung cancer: a population study of the US SEER database …
…, T D'Amico, A Brunelli, H Chen, X Zhi… - Journal of clinical …, 2017 - ascopubs.org
Purpose We investigated the correlation between the number of examined lymph nodes (ELNs)
and correct staging and long-term survival in non–small-cell lung cancer (NSCLC) by …
and correct staging and long-term survival in non–small-cell lung cancer (NSCLC) by …
[HTML][HTML] Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition)
…, F Yu, B Zhang, L Zhang, B Zhao, X Zhi… - … lung cancer research, 2019 - ncbi.nlm.nih.gov
Non-small cell lung cancer (NSCLC) is the most common and fatal tumor worldwide, with
2.1 million new cases and 1.77 million deaths per year (1). With the wider application of …
2.1 million new cases and 1.77 million deaths per year (1). With the wider application of …
Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells
ZHI Gao, Z Xu, MS Hung, YC Lin, T Wang… - Anticancer …, 2009 - ar.iiarjournals.org
Background: Aberrant promoter methylation of Wnt inhibitory factor-1 (WIF-1) is a fundamental
mechanism of epigenetic silencing in human cancers. Epigallocatechin-3-gallate (EGCG) …
mechanism of epigenetic silencing in human cancers. Epigallocatechin-3-gallate (EGCG) …
Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test
…, N Xu, Q Dong, L Chen, Y Yang, X Zhi… - The Journal of …, 2021 - Am Soc Clin Investig
BACKGROUND Current clinical management of patients with pulmonary nodules involves
either repeated low-dose CT (LDCT)/CT scans or invasive procedures, yet causes significant …
either repeated low-dose CT (LDCT)/CT scans or invasive procedures, yet causes significant …
Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells
…, YC Lin, T Wang, M Gong, X Zhi… - Oncology …, 2009 - spandidos-publications.com
Secreted Wingless type (Wnt) ligands have previously been shown to be involved in tumor
developmental processes and oncogenesis. Aberrant promoter methylation of Wnt inhibitory …
developmental processes and oncogenesis. Aberrant promoter methylation of Wnt inhibitory …
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese …
…, L Zhang, C Hu, Y Luo, L Chen, M Ye, J Huang, X Zhi… - 2012 - ascopubs.org
7520 Background: The OPTIMAL study demonstrated significant superiority for E versus GC
in terms of progression-free survival (PFS), objective response rate, tolerability and quality of …
in terms of progression-free survival (PFS), objective response rate, tolerability and quality of …
